Illumina Inc (NASDAQ:ILMN). reported stronger-than-expected earnings for the fourth quarter of 2024, with both earnings per share (EPS) and revenue surpassing analysts' forecasts. Despite the positive ...
Stocktwits on MSN14h
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same PageShares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback